Vir Biotechnology (VIR) Short term Debt (2019 - 2025)

Vir Biotechnology has disclosed Short term Debt across 5 years of filings, most recently posting $17.5 million for Q1 2025.

• Short term Debt for Q1 2025 came in at $17.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2025 was $17.5 million (changed N/A YoY), and the FY2024 annual result was $16.1 million, changed N/A from the prior year.
• Short term Debt came in at $17.5 million for Q1 2025 at Vir Biotechnology, up from $16.1 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $68.5 million in Q3 2021 to a low of $16.1 million in Q4 2024.
• The 3-year median for Short term Debt is $24.4 million (2021), against an average of $30.5 million.
• Peak annual rise in Short term Debt reached 457.45% in 2021, while the deepest fall reached 128.04% in 2021.
• Vir Biotechnology's Short term Debt stood at $68.5 million in 2021, then slumped by 76.55% to $16.1 million in 2024, then grew by 8.97% to $17.5 million in 2025.
• The last three Short term Debt figures came in at $17.5 million (Q1 2025), $16.1 million (Q4 2024), and $68.5 million (Q3 2021), per Business Quant data.